Top

Published in:

01-12-2020 | Metastasis | Review

Roles of circRNAs in the tumour microenvironment

Authors: Qiuge Zhang, Weiwei Wang, Quanbo Zhou, Chen Chen, Weitang Yuan, Jinbo Liu, Xiaoli Li, Zhenqiang Sun

Published in: Molecular Cancer | Issue 1/2020

Abstract

The tumour microenvironment (TME) constitutes the area surrounding the tumour during its development and has been demonstrated to play roles in cancer-related diseases through crosstalk with tumour cells. Circular RNAs (circRNAs) are a subpopulation of endogenous noncoding RNAs (ncRNAs) that are ubiquitously expressed in eukaryotes and have multiple biological functions in the regulation of cancer onset and progression. An increasing number of studies have shown that circRNAs participate in the multifaceted biological regulation of the TME. However, details on the mechanisms involved have remained elusive until now. In this review, we analyse the effects of circRNAs on the TME from various perspectives, including immune surveillance, angiogenesis, hypoxia, matrix remodelling, exo-circRNAs and chemoradiation resistance. Currently, the enormous potential for circRNA use in targeted therapy and as noninvasive biomarkers have drawn our attention. We emphasize the prospect of targeting circRNAs as an essential strategy to regulate TME, overcome cancer resistance and improve therapeutic outcomes.

Zhang QY, Wang FX, Jia KK, Kong LD. Natural Product Interventions for Chemotherapy and Radiotherapy-Induced Side Effects. Front Pharmacol. 2018;9:1253. https://doi.org/10.3389/fphar.2018.01253.CrossRefPubMedPubMedCentral

Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21(3):309–22. https://doi.org/10.1016/j.ccr.2012.02.022.CrossRefPubMed

Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;125(Pt 23):5591–6. https://doi.org/10.1242/jcs.116392.CrossRefPubMed

Hu M, Polyak K. Microenvironmental regulation of cancer development. Curr Opin Genet Dev. 2008;18(1):27–34. https://doi.org/10.1016/j.gde.2007.12.006.CrossRefPubMedPubMedCentral

Chen Y, Liu X, Yuan H, Yang Z, von Roemeling CA, Qie Y, et al. Therapeutic Remodeling of the Tumor Microenvironment Enhances Nanoparticle Delivery. Adv Sci (Weinh). 2019;6(5):1802070. https://doi.org/10.1002/advs.201802070.CrossRef

Ocana MC, Martinez-Poveda B, Quesada AR, Medina MA. Metabolism within the tumor microenvironment and its implication on cancer progression: An ongoing therapeutic target. Med Res Rev. 2019;39(1):70–113. https://doi.org/10.1002/med.21511.CrossRefPubMed

He Y, Liu S, Mattei J, Bunn PA Jr, Zhou C, Chan D. The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC. Drug Des Devel Ther. 2018;12:981–6. https://doi.org/10.2147/dddt.S163304.CrossRefPubMedPubMedCentral

Hameed S, Bhattarai P, Dai Z. Nanotherapeutic approaches targeting angiogenesis and immune dysfunction in tumor microenvironment. Sci China Life Sci. 2018;61(4):380–91. https://doi.org/10.1007/s11427-017-9256-1.CrossRefPubMed

Patel A, Sant S. Hypoxic tumor microenvironment: Opportunities to develop targeted therapies. Biotechnol Adv. 2016;34(5):803–12. https://doi.org/10.1016/j.biotechadv.2016.04.005.CrossRefPubMedPubMedCentral

10.

Bronisz A, Godlewski J, Wallace JA, Merchant AS, Nowicki MO, Mathsyaraja H, et al. Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol. 2011;14(2):159–67. https://doi.org/10.1038/ncb2396.CrossRefPubMedPubMedCentral

11.

Aprelikova O, Yu X, Palla J, Wei BR, John S, Yi M, et al. The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts. Cell Cycle. 2010;9(21):4387–98. https://doi.org/10.4161/cc.9.21.13674.CrossRefPubMedPubMedCentral

12.

Chou J, Shahi P, Werb Z. microRNA-mediated regulation of the tumor microenvironment. Cell Cycle. 2013;12(20):3262–71. https://doi.org/10.4161/cc.26087.CrossRefPubMedPubMedCentral

13.

Wu K, Zhao Z, Liu K, Zhang J, Li G, Wang L. Long noncoding RNA lnc-sox5 modulates CRC tumorigenesis by unbalancing tumor microenvironment. Cell Cycle. 2017;16(13):1295–301. https://doi.org/10.1080/15384101.2017.1317416.CrossRefPubMedPubMedCentral

14.

Lin YH, Wu MH, Yeh CT, Lin KH. Long Non-Coding RNAs as Mediators of Tumor Microenvironment and Liver Cancer Cell Communication. Int J Mol Sci. Int J Mol Sci. 2018;19(12):3742. https://doi.org/10.3390/ijms19123742.CrossRefPubMedCentral

15.

Sun Z, Yang S, Zhou Q, Wang G, Song J, Li Z, et al. Emerging role of exosome-derived long non-coding RNAs in tumor microenvironment. Mol Cancer. 2018;17(1):82. https://doi.org/10.1186/s12943-018-0831-z.CrossRefPubMedPubMedCentral

16.

Chen LL, Yang L. Regulation of circRNA biogenesis. RNA Biol. 2015;12(4):381–8. https://doi.org/10.1080/15476286.2015.1020271.CrossRefPubMedPubMedCentral

17.

Chen B, Huang S. Circular RNA: An emerging non-coding RNA as a regulator and biomarker in cancer. Cancer Lett 2018; 418: 41-50.doi:https://doi.org/10.1016/j.canlet.2018.01.011.CrossRefPubMed

18.

Li Z, Zhou Y, Yang G, He S, Qiu X, Zhang L, et al. Using circular RNA SMARCA5 as a potential novel biomarker for hepatocellular carcinoma. Clin Chim Acta. 2019;492:37–44. https://doi.org/10.1016/j.cca.2019.02.001.CrossRefPubMed

19.

Su H, Zou D, Sun Y, Dai Y. Hypoxia-associated circDENND2A promotes glioma aggressiveness by sponging miR-625-5p. Cell Mol Biol Lett. 2019;24:24. https://doi.org/10.1186/s11658-019-0149-x.CrossRefPubMedPubMedCentral

20.

He Q, Zhao L, Liu Y, Liu X, Zheng J, Yu H, et al. circ-SHKBP1 Regulates the Angiogenesis of U87 Glioma-Exposed Endothelial Cells through miR-544a/FOXP1 and miR-379/FOXP2 Pathways. Mol Ther Nucleic Acids. 2018;10:331–48. https://doi.org/10.1016/j.omtn.2017.12.014.CrossRefPubMed

21.

Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989;8(2):98–101.PubMed

22.

Mendoza M, Khanna C. Revisiting the seed and soil in cancer metastasis. Int J Biochem Cell Biol. 2009;41(7):1452–62. https://doi.org/10.1016/j.biocel.2009.01.015.CrossRefPubMedPubMedCentral

23.

Chen F, Zhuang X, Lin L, Yu P, Wang Y, Shi Y, et al. New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med. 2015;13:45. https://doi.org/10.1186/s12916-015-0278-7.CrossRefPubMedPubMedCentral

24.

Yuan Y, Jiang YC, Sun CK, Chen QM. Role of the tumor microenvironment in tumor progression and the clinical applications (Review). Oncol Rep. 2016;35(5):2499–515. https://doi.org/10.3892/or.2016.4660.CrossRefPubMed

25.

Luo Z, Wang Q, Lau WB, Lau B, Xu L, Zhao L, et al. Tumor microenvironment: The culprit for ovarian cancer metastasis? Cancer Lett. 2016;377(2):174–82. https://doi.org/10.1016/j.canlet.2016.04.038.CrossRefPubMed

26.

Martin M, Wei H, Lu T. Targeting microenvironment in cancer therapeutics. Oncotarget. 2016;7(32):52575–83. https://doi.org/10.18632/oncotarget.9824.CrossRefPubMedPubMedCentral

27.

Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501(7467):346–54. https://doi.org/10.1038/nature12626.CrossRefPubMed

28.

Motz GT, Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol. 2011;11(10):702–11. https://doi.org/10.1038/nri3064.CrossRefPubMed

29.

Altorki NK, Markowitz GJ, Gao D, Port JL, Saxena A, Stiles B, et al. The lung microenvironment: an important regulator of tumour growth and metastasis. Nat Rev Cancer. 2019;19(1):9–31. https://doi.org/10.1038/s41568-018-0081-9.CrossRefPubMedPubMedCentral

30.

Danan M, Schwartz S, Edelheit S, Sorek R. Transcriptome-wide discovery of circular RNAs in Archaea. Nucleic Acids Res. 2012;40(7):3131–42. https://doi.org/10.1093/nar/gkr1009.CrossRefPubMed

31.

Ye CY, Chen L, Liu C, Zhu QH, Fan L. Widespread noncoding circular RNAs in plants. New Phytol. 2015;208(1):88–95. https://doi.org/10.1111/nph.13585.CrossRefPubMed

32.

Lu T, Cui L, Zhou Y, Zhu C, Fan D, Gong H, et al. Transcriptome-wide investigation of circular RNAs in rice. Rna. 2015;21(12):2076–87. https://doi.org/10.1261/rna.052282.115.CrossRefPubMedPubMedCentral

33.

Fan X, Zhang X, Wu X, Guo H, Hu Y, Tang F, et al. Single-cell RNA-seq transcriptome analysis of linear and circular RNAs in mouse preimplantation embryos. Genome Biol. 2015;16:148. https://doi.org/10.1186/s13059-015-0706-1.CrossRefPubMedPubMedCentral

34.

Shen Y, Guo X, Wang W. Identification and characterization of circular RNAs in zebrafish. FEBS Lett. 2017;591(1):213–20. https://doi.org/10.1002/1873-3468.12500.CrossRefPubMed

35.

Wang PL, Bao Y, Yee MC, Barrett SP, Hogan GJ, Olsen MN, et al. Circular RNA is expressed across the eukaryotic tree of life. PLoS One. 2014;9(6):e90859. https://doi.org/10.1371/journal.pone.0090859.CrossRefPubMedPubMedCentral

36.

Rybak-Wolf A, Stottmeister C, Glazar P, Jens M, Pino N, Giusti S, et al. Circular RNAs in the Mammalian Brain Are Highly Abundant, Conserved, and Dynamically Expressed. Mol Cell. 2015;58(5):870–85. https://doi.org/10.1016/j.molcel.2015.03.027.CrossRefPubMed

37.

Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. Rna. 2013;19(2):141–57. https://doi.org/10.1261/rna.035667.112.CrossRefPubMedPubMedCentral

38.

Salzman J, Gawad C, Wang PL, Lacayo N, Brown PO. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS One. 2012;7(2):e30733. https://doi.org/10.1371/journal.pone.0030733.CrossRefPubMedPubMedCentral

39.

Li X, Yang L, Chen LL. The Biogenesis, Functions, and Challenges of Circular RNAs. Mol Cell. 2018;71(3):428–42. https://doi.org/10.1016/j.molcel.2018.06.034.CrossRefPubMed

40.

Dong R, Ma XK, Chen LL, Yang L. Increased complexity of circRNA expression during species evolution. RNA Biol. 2017;14(8):1064–74. https://doi.org/10.1080/15476286.2016.1269999.CrossRefPubMed

41.

Salzman J, Chen RE, Olsen MN, Wang PL, Brown PO. Cell-type specific features of circular RNA expression. PLoS Genet. 2013;9(9):e1003777. https://doi.org/10.1371/journal.pgen.1003777.CrossRefPubMedPubMedCentral

42.

Nicolet BP, Engels S, Aglialoro F, van den Akker E, von Lindern M, Wolkers MC. Circular RNA expression in human hematopoietic cells is widespread and cell-type specific. Nucleic Acids Res. 2018;46(16):8168–80. https://doi.org/10.1093/nar/gky721.CrossRefPubMedPubMedCentral

43.

Zhang P, Zuo Z, Shang W, Wu A, Bi R, Wu J, et al. Identification of differentially expressed circular RNAs in human colorectal cancer. Tumour Biol. 2017;39(3):1010428317694546. https://doi.org/10.1177/1010428317694546.CrossRefPubMed

44.

Westholm JO, Miura P, Olson S, Shenker S, Joseph B, Sanfilippo P, et al. Genome-wide analysis of drosophila circular RNAs reveals their structural and sequence properties and age-dependent neural accumulation. Cell Rep. 2014;9(5):1966–80. https://doi.org/10.1016/j.celrep.2014.10.062.CrossRefPubMedPubMedCentral

45.

Zheng XB, Zhang M, Xu MQ. Detection and characterization of ciRS-7: a potential promoter of the development of cancer. Neoplasma. 2017;64(3):321–8. https://doi.org/10.4149/neo_2017_301.CrossRefPubMed

46.

Wang R, Zhang S, Chen X, Li N, Li J, Jia R, et al. CircNT5E Acts as a Sponge of miR-422a to Promote Glioblastoma Tumorigenesis. Cancer Res. 2018;78(17):4812–25. https://doi.org/10.1158/0008-5472.Can-18-0532.CrossRefPubMed

47.

Wu J, Jiang Z, Chen C, Hu Q, Fu Z, Chen J, et al. CircIRAK3 sponges miR-3607 to facilitate breast cancer metastasis. Cancer Lett. 2018;430:179–92. https://doi.org/10.1016/j.canlet.2018.05.033.CrossRefPubMed

48.

Hansen TB, Kjems J, Damgaard CK. Circular RNA and miR-7 in cancer. Cancer Res. 2013;73(18):5609–12. https://doi.org/10.1158/0008-5472.Can-13-1568.CrossRefPubMed

49.

Wang K, Sun Y, Tao W, Fei X, Chang C. Androgen receptor (AR) promotes clear cell renal cell carcinoma (ccRCC) migration and invasion via altering the circHIAT1/miR-195-5p/29a-3p/29c-3p/CDC42 signals. Cancer Lett. 2017;394:1–12. https://doi.org/10.1016/j.canlet.2016.12.036.CrossRefPubMed

50.

Conn SJ, Pillman KA, Toubia J, Conn VM, Salmanidis M, Phillips CA, et al. The RNA binding protein quaking regulates formation of circRNAs. Cell. 2015;160(6):1125–34. https://doi.org/10.1016/j.cell.2015.02.014.CrossRefPubMed

51.

Abdelmohsen K, Panda AC, Munk R, Grammatikakis I, Dudekula DB, De S, et al. Identification of HuR target circular RNAs uncovers suppression of PABPN1 translation by CircPABPN1. RNA Biol. 2017;14(3):361–9. https://doi.org/10.1080/15476286.2017.1279788.CrossRefPubMedPubMedCentral

52.

Yang ZG, Awan FM, Du WW, Zeng Y, Lyu J. Wu, et al. The Circular RNA Interacts with STAT3, Increasing Its Nuclear Translocation and Wound Repair by Modulating Dnmt3a and miR-17 Function. Mol Ther. 2017;25(9):2062–74. https://doi.org/10.1016/j.ymthe.2017.05.022.CrossRefPubMedPubMedCentral

53.

Zang J, Lu D, Xu A. The interaction of circRNAs and RNA binding proteins: An important part of circRNA maintenance and function. J Neurosci Res. 2018. https://doi.org/10.1002/jnr.24356.CrossRefPubMed

54.

Du WW, Yang W, Chen Y, Wu ZK, Foster FS, Yang Z, et al. Foxo3 circular RNA promotes cardiac senescence by modulating multiple factors associated with stress and senescence responses. Eur Heart J. 2017;38(18):1402–12. https://doi.org/10.1093/eurheartj/ehw001.CrossRefPubMed

55.

Du WW, Fang L, Yang W, Wu N, Awan FM, Yang Z, et al. Induction of tumor apoptosis through a circular RNA enhancing Foxo3 activity. Cell Death Differ. 2017;24(2):357–70. https://doi.org/10.1038/cdd.2016.133.CrossRefPubMed

56.

Du WW, Yang W, Liu E, Yang Z, Dhaliwal P, Yang BB. Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2. Nucleic Acids Res. 2016;44(6):2846–58. https://doi.org/10.1093/nar/gkw027.CrossRefPubMedPubMedCentral

57.

Zheng X, Chen L, Zhou Y, Wang Q, Zheng Z, Xu B, et al. A novel protein encoded by a circular RNA circPPP1R12A promotes tumor pathogenesis and metastasis of colon cancer via Hippo-YAP signaling. Mol Cancer. 2019;18(1):47. https://doi.org/10.1186/s12943-019-1010-6.CrossRefPubMedPubMedCentral

58.

Ye L, Zhang Q, Cheng Y, Chen X, Wang G, Shi M, et al. Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1(+) regulatory B cell expansion. J Immunother Cancer. 2018;6(1):145. https://doi.org/10.1186/s40425-018-0451-6.CrossRefPubMedPubMedCentral

59.

Zhang Y, Zhang XO, Chen T, Xiang JF, Yin QF, Xing YH, et al. Circular intronic long noncoding RNAs. Mol Cell. 2013;51(6):792–806. https://doi.org/10.1016/j.molcel.2013.08.017.CrossRefPubMed

60.

Yang Q, Du WW, Wu N, Yang W, Awan FM, Fang L, et al. A circular RNA promotes tumorigenesis by inducing c-myc nuclear translocation. Cell Death Differ. 2017;24(9):1609–20. https://doi.org/10.1038/cdd.2017.86.CrossRefPubMedPubMedCentral

61.

Bach DH, Lee SK, Sood AK. Circular RNAs in Cancer. Mol Ther Nucleic Acids. 2019;16:118–29. https://doi.org/10.1016/j.omtn.2019.02.005.CrossRefPubMedPubMedCentral

62.

Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137–48. https://doi.org/10.1016/j.immuni.2004.07.017.CrossRefPubMed

63.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. https://doi.org/10.1016/j.cell.2011.02.013.CrossRefPubMed

64.

Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565–70. https://doi.org/10.1126/science.1203486.CrossRefPubMed

65.

Chen YG, Kim MV, Chen X, Batista PJ, Aoyama S, Wilusz JE, et al. Sensing Self and Foreign Circular RNAs by Intron Identity. Mol Cell. 2017;67(2):228–238.e225. https://doi.org/10.1016/j.molcel.2017.05.022.CrossRefPubMedPubMedCentral

66.

Barbalat R, Ewald SE, Mouchess ML, Barton GM. Nucleic acid recognition by the innate immune system. Annu Rev Immunol. 2011;29:185–214. https://doi.org/10.1146/annurev-immunol-031210-101340.CrossRefPubMed

67.

Wu J, Chen ZJ. Innate immune sensing and signaling of cytosolic nucleic acids. Annu Rev Immunol. 2014;32:461–88. https://doi.org/10.1146/annurev-immunol-032713-120156.CrossRefPubMed

68.

Iurescia S, Fioretti D, Rinaldi M. Nucleic Acid Sensing Machinery: Targeting Innate Immune System for Cancer Therapy. Recent Pat Anticancer Drug Discov. 2018;13(1):2–17. https://doi.org/10.2174/1574892812666171030163804.CrossRefPubMed

69.

Bourquin C, Pommier A, Hotz C. Harnessing the immune system to fight cancer with Toll-like receptor and RIG-I-like receptor agonists. Pharmacol Res. 2019;104192. https://doi.org/10.1016/j.phrs.2019.03.001.

70.

Maybruck BT, Pfannenstiel LW, Diaz-Montero M, Gastman BR. Tumor-derived exosomes induce CD8(+) T cell suppressors. J Immunother Cancer. 2017;5(1):65. https://doi.org/10.1186/s40425-017-0269-7.CrossRefPubMedPubMedCentral

71.

Ning Y, Shen K, Wu Q, Sun X, Bai Y, Xie Y, et al. Tumor exosomes block dendritic cells maturation to decrease the T cell immune response. Immunol Lett. 2018;199:36–43. https://doi.org/10.1016/j.imlet.2018.05.002.CrossRefPubMed

72.

Li P, Liu C, Yu Z, Wu M. New Insights into Regulatory T Cells: Exosome- and Non-Coding RNA-Mediated Regulation of Homeostasis and Resident Treg Cells. Front Immunol. 2016;7:574. https://doi.org/10.3389/fimmu.2016.00574.CrossRefPubMedPubMedCentral

73.

Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–9. https://doi.org/10.1038/ncb1596.CrossRefPubMed

74.

Dai X, Chen C, Yang Q, Xue J, Chen X, Sun B, et al. Exosomal circRNA_100284 from arsenite-transformed cells, via microRNA-217 regulation of EZH2, is involved in the malignant transformation of human hepatic cells by accelerating the cell cycle and promoting cell proliferation. Cell Death Dis. 2018;9(5):454. https://doi.org/10.1038/s41419-018-0485-1.CrossRefPubMedPubMedCentral

75.

Dou Y, Cha DJ, Franklin JL, Higginbotham JN, Jeppesen DK, Weaver AM, et al. Circular RNAs are down-regulated in KRAS mutant colon cancer cells and can be transferred to exosomes. Sci Rep. 2016;6:37982. https://doi.org/10.1038/srep37982.CrossRefPubMedPubMedCentral

76.

Lasda E, Parker R. Circular RNAs Co-Precipitate with Extracellular Vesicles: A Possible Mechanism for circRNA Clearance. PLoS One. 2016;11(2):e0148407. https://doi.org/10.1371/journal.pone.0148407.CrossRefPubMedPubMedCentral

77.

Weng Q, Chen M, Li M, Zheng YF, Shao G, Fan W, et al. Global microarray profiling identified hsa_circ_0064428 as a potential immune-associated prognosis biomarker for hepatocellular carcinoma. J Med Genet. 2019;56(1):32–8. https://doi.org/10.1136/jmedgenet-2018-105440.CrossRefPubMed

78.

Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704. https://doi.org/10.1146/annurev.immunol.26.021607.090331.CrossRefPubMed

79.

Zhang XL, Xu LL, Wang F. Hsa_circ_0020397 regulates colorectal cancer cell viability, apoptosis and invasion by promoting the expression of the miR-138 targets TERT and PD-L1. Cell Biol Int. 2017;41(9):1056–64. https://doi.org/10.1002/cbin.10826.CrossRefPubMed

80.

Shi MH, Xing YF, Zhang ZL, Huang JA, Chen YJ. Effect of soluble PD-L1 released by lung cancer cells in regulating the function of T lymphocytes. Zhonghua Zhong Liu Za Zhi. 2013;35(2):85–8. https://doi.org/10.3760/cma.j.issn.0253-3766.2013.02.002.CrossRefPubMed

81.

Xu C, Fillmore CM, Koyama S, Wu H, Zhao Y, Chen Z, et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell. 2014;25(5):590–604. https://doi.org/10.1016/j.ccr.2014.03.033.CrossRefPubMedPubMedCentral

82.

Gevensleben H, Dietrich D, Golletz C, Steiner S, Jung M, Thiesler T, et al. The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer. Clin Cancer Res. 2016;22(8):1969–77. https://doi.org/10.1158/1078-0432.Ccr-15-2042.CrossRefPubMed

83.

Passardi A, Canale M, Valgiusti M, Ulivi P. Immune Checkpoints as a Target for Colorectal Cancer Treatment. Int J Mol Sci. 2017;18(6). https://doi.org/10.3390/ijms18061324.CrossRefPubMedCentral

84.

Hui R, Garon EB, Goldman JW, Leighl NB, Hellmann MD, Patnaik A, et al. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Ann Oncol. 2017;28(4):874–81. https://doi.org/10.1093/annonc/mdx008.CrossRefPubMedPubMedCentral

85.

McCall NS, Dicker AP, Lu B. Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer. Clin Cancer Res. 2018;24(6):1271–6. https://doi.org/10.1158/1078-0432.Ccr-17-3269.CrossRefPubMed

86.

Sonpavde G. PD-1 and PD-L1 Inhibitors as Salvage Therapy for Urothelial Carcinoma. N Engl J Med. 2017;376(11):1073–4. https://doi.org/10.1056/NEJMe1701182.CrossRefPubMed

87.

Li D, Wang X, Yang M, Kan Q, Duan Z. miR3609 sensitizes breast cancer cells to adriamycin by blocking the programmed death-ligand 1 immune checkpoint. Exp Cell Res. 2019;380(1):20–8. https://doi.org/10.1016/j.yexcr.2019.03.025.CrossRefPubMed

88.

Xie WB, Liang LH, Wu KG, Wang LX, He X, Song C, et al. MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC. Cell Physiol Biochem. 2018;46(2):654–63. https://doi.org/10.1159/000488634.CrossRefPubMed

89.

Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology. 2007;121(1):1–14. https://doi.org/10.1111/j.1365-2567.2007.02587.x.CrossRefPubMedPubMedCentral

90.

Wang WT, Zhu HY, Wu YJ, Xia Y, Wu JZ, Wu W, et al. Elevated absolute NK cell counts in peripheral blood predict good prognosis in chronic lymphocytic leukemia. J Cancer Res Clin Oncol. 2018;144(3):449–57. https://doi.org/10.1007/s00432-017-2568-2.CrossRefPubMed

91.

Xu B, Chen L, Li J, Zheng X, Shi L, Wu C, et al. Prognostic value of tumor infiltrating NK cells and macrophages in stage II+III esophageal cancer patients. Oncotarget. 2016;7(46):74904–16. https://doi.org/10.18632/oncotarget.12484.CrossRefPubMedPubMedCentral

92.

Ma Y, Zhang C, Zhang B, Yu H, Yu Q. circRNA of AR-suppressed PABPC1 91 bp enhances the cytotoxicity of natural killer cells against hepatocellular carcinoma via upregulating UL16 binding protein 1. Oncol Lett. 2019;17(1):388–97. https://doi.org/10.3892/ol.2018.9606.CrossRefPubMed

93.

Ou ZL, Luo Z, Wei W, Liang S, Gao TL, Lu YB. Hypoxia-induced shedding of MICA and HIF1A-mediated immune escape of pancreatic cancer cells from NK cells: role of circ_0000977/miR-153 axis. RNA Biol. 2019:1–12. https://doi.org/10.1080/15476286.2019.1649585.CrossRefPubMedPubMedCentral

94.

Viallard C, Larrivee B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis. 2017;20(4):409–26. https://doi.org/10.1007/s10456-017-9562-9.CrossRefPubMed

95.

Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2010;1805(1):105–17. https://doi.org/10.1016/j.bbcan.2009.11.002.CrossRefPubMed

96.

Li J, Li H, Lv X, Yang Z, Gao M, Bi Y, et al. Diagnostic performance of circular RNAs in human cancers: A systematic review and meta-analysis. Mol Genet Genomic Med. 2019:e749. https://doi.org/10.1002/mgg3.749.

97.

Zhong Z, Huang M, Lv M, He Y, Duan C, Zhang L, et al. Circular RNA MYLK as a competing endogenous RNA promotes bladder cancer progression through modulating VEGFA/VEGFR2 signaling pathway. Cancer Lett. 2017;403:305–17. https://doi.org/10.1016/j.canlet.2017.06.027.CrossRefPubMed

98.

Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med. 2013;273(2):114–27. https://doi.org/10.1111/joim.12019.CrossRefPubMed

99.

Cao W, Zhao Y, Wang L, Huang X. Circ0001429 regulates progression of bladder cancer through binding miR-205-5p and promoting VEGFA expression. Cancer Biomark. 2019;25(1):101–13. https://doi.org/10.3233/cbm-182380.CrossRefPubMed

100.

Meng Q, Li S, Liu Y, Zhang S, Jin J, Zhang Y, et al. Circular RNA circSCAF11 Accelerates the Glioma Tumorigenesis through the miR-421/SP1/VEGFA Axis. Mol Ther Nucleic Acids. 2019;17:669–77. https://doi.org/10.1016/j.omtn.2019.06.022.CrossRefPubMedPubMedCentral

101.

Yang P, Qiu Z, Jiang Y, Dong L, Yang W, Gu C, et al. Silencing of cZNF292 circular RNA suppresses human glioma tube formation via the Wnt/beta-catenin signaling pathway. Oncotarget. 2016;7(39):63449–55. https://doi.org/10.18632/oncotarget.11523.CrossRefPubMedPubMedCentral

102.

Boeckel JN, Jae N, Heumuller AW, Chen W, Boon RA, Stellos K, et al. Identification and Characterization of Hypoxia-Regulated Endothelial Circular RNA. Circ Res. 2015;117(10):884–90. https://doi.org/10.1161/circresaha.115.306319.CrossRefPubMed

103.

Yang W, Liu Y, Gao R, Xiu Z, Sun T. Knockdown of cZNF292 suppressed hypoxic human hepatoma SMMC7721 cell proliferation, vasculogenic mimicry, and radioresistance. Cell Signal. 2019;60:122–35. https://doi.org/10.1016/j.cellsig.2019.04.011.CrossRefPubMed

104.

Dang RY, Liu FL, Li Y. Circular RNA hsa_circ_0010729 regulates vascular endothelial cell proliferation and apoptosis by targeting the miR-186/HIF-1alpha axis. Biochem Biophys Res Commun. 2017;490(2):104–10. https://doi.org/10.1016/j.bbrc.2017.05.164.CrossRefPubMed

105.

He Z, Ruan X, Liu X, Zheng J, Liu Y, Liu L, et al. FUS/circ_002136/miR-138-5p/SOX13 feedback loop regulates angiogenesis in Glioma. J Exp Clin Cancer Res. 2019;38(1):65. https://doi.org/10.1186/s13046-019-1065-7.CrossRefPubMedPubMedCentral

106.

He Q, Zhao L, Liu X, Zheng J, Liu Y, Liu L, et al. MOV10 binding circ-DICER1 regulates the angiogenesis of glioma via miR-103a-3p/miR-382-5p mediated ZIC4 expression change. J Exp Clin Cancer Res. 2019;38(1):9. https://doi.org/10.1186/s13046-018-0990-1.CrossRefPubMedPubMedCentral

107.

Li Y, Zheng F, Xiao X, Xie F, Tao D, Huang C, et al. CircHIPK3 sponges miR-558 to suppress heparanase expression in bladder cancer cells. EMBO Rep. 2017;18(9):1646–59. https://doi.org/10.15252/embr.201643581.CrossRefPubMedPubMedCentral

108.

Barbagallo D, Caponnetto A, Brex D, Mirabella F, Barbagallo C, Lauretta G, et al. CircSMARCA5 Regulates VEGFA mRNA Splicing and Angiogenesis in Glioblastoma Multiforme Through the Binding of SRSF1. Cancers (Basel). 2019;11(2). https://doi.org/10.3390/cancers11020194.CrossRefPubMedCentral

109.

Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699–708. https://doi.org/10.1056/NEJMoa1308573.CrossRefPubMedPubMedCentral

110.

Li CY, Ma L, Yu B. Circular RNA hsa_circ_0003575 regulates oxLDL induced vascular endothelial cells proliferation and angiogenesis. Biomed Pharmacother. 2017;95:1514–9. https://doi.org/10.1016/j.biopha.2017.09.064.CrossRefPubMed

111.

Chouaib S, Kieda C, Benlalam H, Noman MZ, Mami-Chouaib F, Ruegg C. Endothelial cells as key determinants of the tumor microenvironment: interaction with tumor cells, extracellular matrix and immune killer cells. Crit Rev Immunol. 2010;30(6):529–45.CrossRefPubMed

112.

Li J, Li Z, Jiang P, Peng M, Zhang X, Chen K, et al. Circular RNA IARS (circ-IARS) secreted by pancreatic cancer cells and located within exosomes regulates endothelial monolayer permeability to promote tumor metastasis. J Exp Clin Cancer Res. 2018;37(1):177. https://doi.org/10.1186/s13046-018-0822-3.CrossRefPubMedPubMedCentral

113.

Li Y, Ye D. Cancer therapy by targeting hypoxia-inducible factor-1. Curr Cancer Drug Targets. 2010;10(7):782–96.CrossRefPubMed

114.

Huang Y, Lin D, Taniguchi CM. Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe? Sci China Life Sci. 2017;60(10):1114–24. https://doi.org/10.1007/s11427-017-9178-y.CrossRefPubMedPubMedCentral

115.

Liang G, Liu Z, Tan L, Su AN, Jiang WG, Gong C. HIF1alpha-associated circDENND4C Promotes Proliferation of Breast Cancer Cells in Hypoxic Environment. Anticancer Res. 2017;37(8):4337–43. https://doi.org/10.21873/anticanres.11827.CrossRefPubMed

116.

Ren S, Liu J, Feng Y, Li Z, He L, Li L, et al. Knockdown of circDENND4C inhibits glycolysis, migration and invasion by up-regulating miR-200b/c in breast cancer under hypoxia. J Exp Clin Cancer Res. 2019;38(1):388. https://doi.org/10.1186/s13046-019-1398-2.CrossRefPubMedPubMedCentral

117.

Theocharis AD, Skandalis SS, Gialeli C, Karamanos NK. Extracellular matrix structure. Adv Drug Deliv Rev. 2016;97:4–27. https://doi.org/10.1016/j.addr.2015.11.001.CrossRefPubMed

118.

Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000;18(5):1135–49. https://doi.org/10.1200/jco.2000.18.5.1135.CrossRefPubMed

119.

Zhang H, Zhu L, Bai M, Liu Y, Zhan Y, Deng T, et al. Exosomal circRNA derived from gastric tumor promotes white adipose browning by targeting the miR-133/PRDM16 pathway. Int J Cancer. 2019;144(10):2501–15. https://doi.org/10.1002/ijc.31977.CrossRefPubMed

120.

Li P, Chen H, Chen S, Mo X, Li T, Xiao B, et al. Circular RNA 0000096 affects cell growth and migration in gastric cancer. Br J Cancer. 2017;116(5):626–33. https://doi.org/10.1038/bjc.2016.451.CrossRefPubMedPubMedCentral

121.

He C, Huang C, Zhou R, Yu H. CircLMNB1 promotes colorectal cancer by regulating cell proliferation, apoptosis and epithelial-mesenchymal transition. Onco Targets Ther. 2019;12:6349–59. https://doi.org/10.2147/ott.S204741.CrossRefPubMedPubMedCentral

122.

Yang J, Cong X, Ren M, Sun H, Liu T, Chen G, et al. Circular RNA hsa_circRNA_0007334 is Predicted to Promote MMP7 and COL1A1 Expression by Functioning as a miRNA Sponge in Pancreatic Ductal Adenocarcinoma. J Oncol. 2019;2019:7630894. https://doi.org/10.1155/2019/7630894.CrossRefPubMedPubMedCentral

123.

Yamamoto K, Murphy G, Troeberg L. Extracellular regulation of metalloproteinases. Matrix Biol. 2015;44-46:255–63. https://doi.org/10.1016/j.matbio.2015.02.007.CrossRefPubMed

124.

Yu J, Xu QG, Wang ZG, Yang Y, Zhang L, Ma JZ, et al. Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma. J Hepatol. 2018;68(6):1214–27. https://doi.org/10.1016/j.jhep.2018.01.012.CrossRefPubMed

125.

Lee Y, El Andaloussi S, Wood MJ. Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum Mol Genet. 2012;21(R1):R125–34. https://doi.org/10.1093/hmg/dds317.CrossRefPubMed

126.

Shao H, Im H, Castro CM, Breakefield X, Weissleder R, Lee H. New Technologies for Analysis of Extracellular Vesicles. Chem Rev. 2018;118(4):1917–50. https://doi.org/10.1021/acs.chemrev.7b00534.CrossRefPubMedPubMedCentral

127.

Balaj L, Lessard R, Dai L, Cho YJ, Pomeroy SL, Breakefield XO, et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun. 2011;2:180. https://doi.org/10.1038/ncomms1180.CrossRefPubMed

128.

Kahlert C, Melo SA, Protopopov A, Tang J, Seth S, Koch M, et al. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem. 2014;289(7):3869–75. https://doi.org/10.1074/jbc.C113.532267.CrossRefPubMedPubMedCentral

129.

Tetta C, Ghigo E, Silengo L, Deregibus MC, Camussi G. Extracellular vesicles as an emerging mechanism of cell-to-cell communication. Endocrine. 2013;44(1):11–9. https://doi.org/10.1007/s12020-012-9839-0.CrossRefPubMed

130.

Yoshimura A, Sawada K, Nakamura K, Kinose Y, Nakatsuka E, Kobayashi M, et al. Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells. BMC Cancer. 2018;18(1):1065. https://doi.org/10.1186/s12885-018-4974-5.CrossRefPubMedPubMedCentral

131.

Li Y, Zheng Q, Bao C, Li S, Guo W, Zhao J, et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res. 2015;25(8):981–4. https://doi.org/10.1038/cr.2015.82.CrossRefPubMedPubMedCentral

132.

Xu Z, Li P, Fan L, Wu M. The Potential Role of circRNA in Tumor Immunity Regulation and Immunotherapy. Front Immunol. 2018;9:9. https://doi.org/10.3389/fimmu.2018.00009.CrossRefPubMedPubMedCentral

133.

Bai H, Lei K, Huang F, Jiang Z, Zhou X. Exo-circRNAs: a new paradigm for anticancer therapy. Mol Cancer. 2019;18(1):56. https://doi.org/10.1186/s12943-019-0986-2.CrossRefPubMedPubMedCentral

134.

Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, et al. Role of tumor microenvironment in tumorigenesis. J Cancer. 2017;8(5):761–73. https://doi.org/10.7150/jca.17648.CrossRefPubMedPubMedCentral

135.

Zhang H, Deng T, Ge S, Liu Y, Bai M, Zhu K, et al. Exosome circRNA secreted from adipocytes promotes the growth of hepatocellular carcinoma by targeting deubiquitination-related USP7. Oncogene. 2019;38(15):2844–59. https://doi.org/10.1038/s41388-018-0619-z.CrossRefPubMed

136.

Wang Z, Chen JQ, Liu JL, Tian L. Exosomes in tumor microenvironment: novel transporters and biomarkers. J Transl Med. 2016;14(1):297. https://doi.org/10.1186/s12967-016-1056-9.CrossRefPubMedPubMedCentral

137.

Chen W, Jiang J, Xia W, Huang J. Tumor-Related Exosomes Contribute to Tumor-Promoting Microenvironment: An Immunological Perspective. J Immunol Res. 2017;2017:1073947. https://doi.org/10.1155/2017/1073947.CrossRefPubMedPubMedCentral

138.

Roma-Rodrigues C, Raposo LR, Cabral R, Paradinha F, Baptista PV, Fernandes AR. Tumor Microenvironment Modulation via Gold Nanoparticles Targeting Malicious Exosomes: Implications for Cancer Diagnostics and Therapy. Int J Mol Sci. 2017;18(1). https://doi.org/10.3390/ijms18010162.CrossRefPubMedCentral

139.

McGee HM, Jiang D, Soto-Pantoja DR, Nevler A, Giaccia AJ, Woodward WA. Targeting the Tumor Microenvironment in Radiation Oncology: Proceedings from the 2018 ASTRO-AACR Research Workshop. Clin Cancer Res. 2019;25(10):2969–74. https://doi.org/10.1158/1078-0432.Ccr-18-3781.CrossRefPubMedPubMedCentral

140.

Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, et al. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 2000;60(19):5565–70.PubMed

141.

Moeller BJ, Dreher MR, Rabbani ZN, Schroeder T, Cao Y, Li CY, et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell. 2005;8(2):99–110. https://doi.org/10.1016/j.ccr.2005.06.016.CrossRefPubMed

142.

Karar J, Maity A. Modulating the tumor microenvironment to increase radiation responsiveness. Cancer Biol Ther. 2009;8(21):1994–2001. https://doi.org/10.4161/cbt.8.21.9988.CrossRefPubMed

143.

Chen T, Luo J, Gu Y, Huang J, Luo Q, Yang Y. Comprehensive analysis of circular RNA profiling in AZD9291-resistant non-small cell lung cancer cell lines. Thorac Cancer. 2019;10(4):930–41. https://doi.org/10.1111/1759-7714.13032.CrossRefPubMedPubMedCentral

144.

Xiong W, Ai YQ, Li YF, Ye Q, Chen ZT, Qin JY, et al. Microarray Analysis of Circular RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Biomed Res Int. 2017;2017:8421614. https://doi.org/10.1155/2017/8421614.CrossRefPubMedPubMedCentral

145.

Shao F, Huang M, Meng F, Huang Q. Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma. Front Pharmacol. 2018;9:584. https://doi.org/10.3389/fphar.2018.00584.CrossRefPubMedPubMedCentral

146.

Sang Y, Chen B, Song X, Li Y, Liang Y, Han D, et al. circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast. Cancer. Mol Ther. 2019. https://doi.org/10.1016/j.ymthe.2019.05.011.CrossRefPubMedPubMedCentral

147.

Su H, Lin F, Deng X, Shen L, Fang Y, Fei Z, et al. Profiling and bioinformatics analyses reveal differential circular RNA expression in radioresistant esophageal cancer cells. J Transl Med. 2016;14(1):225. https://doi.org/10.1186/s12967-016-0977-7.CrossRefPubMedPubMedCentral

148.

Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol. 2012;9(12):674–87. https://doi.org/10.1038/nrclinonc.2012.171.CrossRefPubMed

149.

Ishii H, Iwatsuki M, Ieta K, Ohta D, Haraguchi N, Mimori K, et al. Cancer stem cells and chemoradiation resistance. Cancer Science. 2008;99(10):1871–7. https://doi.org/10.1111/j.1349-7006.2008.00914.x.CrossRefPubMed

150.

Cheng CC, Chao WT, Liao CC, Shih JH, Lai YS, Hsu YH, et al. The Roles Of Angiogenesis And Cancer Stem Cells In Sorafenib Drug Resistance In Hepatocellular Carcinoma. Oncotargets Therapy. 2019;12:8217–27. https://doi.org/10.2147/Ott.S217468.CrossRefPubMedPubMedCentral

151.

Mattern J. Role of angiogenesis in drug resistance. Anticancer Research. 2001;21(6b):4265–70.PubMed

152.

Wu Y, Zhang Y, Niu M, Shi Y, Liu H, Yang D, et al. Whole-Transcriptome Analysis of CD133+CD144+ Cancer Stem Cells Derived from Human Laryngeal Squamous Cell Carcinoma Cells. Cell Physiol Biochem. 2018;47(4):1696–710. https://doi.org/10.1159/000490992.CrossRefPubMed

153.

Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol. 2012;6(2):140–6. https://doi.org/10.1016/j.molonc.2012.01.010.CrossRefPubMedPubMedCentral

154.

Jafari GF. Circular RNA in Saliva. Adv Exp Med Biol. 2018;1087:131–9. https://doi.org/10.1007/978-981-13-1426-1_11.CrossRef

155.

Lu R, Shao Y, Ye G, Xiao B, Guo J. Low expression of hsa_circ_0006633 in human gastric cancer and its clinical significances. Tumour Biol. 2017;39(6):1010428317704175. https://doi.org/10.1177/1010428317704175.CrossRefPubMed

156.

Yin WB, Yan MG, Fang X, Guo JJ, Xiong W, Zhang RP. Circulating circular RNA hsa_circ_0001785 acts as a diagnostic biomarker for breast cancer detection. Clin Chim Acta. 2018;487:363–8. https://doi.org/10.1016/j.cca.2017.10.011.CrossRefPubMed

157.

Zhao Q, Chen S, Li T, Xiao B, Zhang X. Clinical values of circular RNA 0000181 in the screening of gastric cancer. J Clin Lab Anal. 2018;32(4):e22333. https://doi.org/10.1002/jcla.22333.CrossRefPubMed

158.

Chen S, Li T, Zhao Q, Xiao B, Guo J. Using circular RNA hsa_circ_0000190 as a new biomarker in the diagnosis of gastric cancer. Clin Chim Acta. 2017;466:167–71. https://doi.org/10.1016/j.cca.2017.01.025.CrossRefPubMed

159.

Wang Q, Chen J, Wang A, Sun L, Qian L, Zhou X, et al. Differentially expressed circRNAs in melanocytes and melanoma cells and their effect on cell proliferation and invasion. Oncol Rep. 2018;39(4):1813–24. https://doi.org/10.3892/or.2018.6263.CrossRefPubMed

160.

Xu H, Wang C, Song H, Xu Y, Ji G. RNA-Seq profiling of circular RNAs in human colorectal Cancer liver metastasis and the potential biomarkers. Mol Cancer. 2019;18(1):8. https://doi.org/10.1186/s12943-018-0932-8.CrossRefPubMedPubMedCentral

161.

Wang T, Wang X, Du Q, Wu N, Liu X, Chen Y, et al. The circRNA circP4HB promotes NSCLC aggressiveness and metastasis by sponging miR-133a-5p. Biochem Biophys Res Commun. 2019;513(4):904–11. https://doi.org/10.1016/j.bbrc.2019.04.108.CrossRefPubMed

162.

Guo J, Duan H, Li Y, Yang L, Yuan L. A novel circular RNA circ-ZNF652 promotes hepatocellular carcinoma metastasis through inducing snail-mediated epithelial-mesenchymal transition by sponging miR-203/miR-502-5p. Biochem Biophys Res Commun. 2019;513(4):812–9. https://doi.org/10.1016/j.bbrc.2019.03.214.CrossRefPubMed

163.

Jin P, Huang Y, Zhu P, Zou Y, Shao T, Wang O. CircRNA circHIPK3 serves as a prognostic marker to promote glioma progression by regulating miR-654/IGF2BP3 signaling. Biochem Biophys Res Commun. 2018;503(3):1570–4. https://doi.org/10.1016/j.bbrc.2018.07.081.CrossRefPubMed

164.

Chen B, Wei W, Huang X, Xie X, Kong Y, Dai D, et al. circEPSTI1 as a Prognostic Marker and Mediator of Triple-Negative Breast Cancer Progression. Theranostics. 2018;8(14):4003–15. https://doi.org/10.7150/thno.24106.CrossRefPubMedPubMedCentral

165.

Tang H, Huang X, Wang J, Yang L, Kong Y, Gao G, et al. circKIF4A acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer. 2019;18(1):23–Mol Cancer. https://doi.org/10.1186/s12943-019-0946-x.

166.

Weng W, Wei Q, Toden S, Yoshida K, Nagasaka T, Fujiwara T, et al. Circular RNA ciRS-7-A Promising Prognostic Biomarker and a Potential Therapeutic Target in Colorectal Cancer. Clin Cancer Res. 2017;23(14):3918–28. https://doi.org/10.1158/1078-0432.Ccr-16-2541.CrossRefPubMedPubMedCentral

167.

Nie WB, Zhao LM, Guo R, Wang MX, Ye FG. Circular RNA circ-NT5C2 acts as a potential novel biomarker for prognosis of osteosarcoma. Eur Rev Med Pharmacol Sci. 2018;22(19):6239–44. https://doi.org/10.26355/eurrev_201810_16030.CrossRefPubMed

168.

Ou ZL, Luo Z, Wei W, Liang S, Gao TL, Lu YB. Hypoxia-induced shedding of MICA and HIF1A-mediated immune escape of pancreatic cancer cells from NK cells: role of circ_0000977/miR-153 axis. RNA Biol. 2019;16(11):1592–603. https://doi.org/10.1080/15476286.2019.1649585.CrossRefPubMedPubMedCentral

169.

Su H. Hypoxia-associated circDENND2A promotes glioma aggressiveness by sponging miR-625-5p. 2019;24. https://doi.org/10.1186/s11658-019-0149-x.

Title: Roles of circRNAs in the tumour microenvironment
Authors: Qiuge Zhang
Weiwei Wang
Quanbo Zhou
Chen Chen
Weitang Yuan
Jinbo Liu
Xiaoli Li
Zhenqiang Sun
Publication date: 01-12-2020
Publisher: BioMed Central
Keyword: Metastasis
Published in: Molecular Cancer / Issue 1/2020
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/s12943-019-1125-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

Programmable N6-methyladenosine modification of CDCP1 mRNA by RCas9-methyltransferase like 3 conjugates promotes bladder cancer development

Cytosine methylation of mature microRNAs inhibits their functions and is associated with poor prognosis in glioblastoma multiforme

Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance

Circular RNAs in the tumour microenvironment

Long non-coding RNA UCA1 promotes malignant phenotypes of renal cancer cells by modulating the miR-182-5p/DLL4 axis as a ceRNA

Novel insight into the regulatory roles of diverse RNA modifications: Re-defining the bridge between transcription and translation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer